{"doi":"10.1101/2025.02.17.25322322","title":"Clinical Progression on CDR-SB <sup>©</sup> : Progression Free Time at Each 0.5-unit Level in Dominantly Inherited and Sporadic Alzheimer’s Disease Populations","abstract":"INTRODUCTION: CDR-SB is a reliable and clinically meaningful composite for assessing treatment effects in Alzheimer's disease (AD) clinical trials. Small CDR-SB differences at the end of a trial often lead to controversy in deriving clinically meaningful interpretations. METHODS: We estimated progression-free time participants remained at each 0.5-unit CDR-SB increment in dominantly inherited AD (DIAD) and sporadic AD populations, evaluating its potential as an alternative measure of treatment effects. RESULTS: Progression-free time is longer at CDR-SB ≤ 2.0 (1-2 years) and shorter at CDR-SB ≥ 5 (0.33 or less) in the ADNI cohort. The DIAD cohort showed similar but shorter times. Using progression-free time, continuous lecanemab treatment for three years is estimated to delay disease progression by 0.7 years in the sporadic population. DISCUSSION: Progression-free time provides a benchmark for expressing clinical progression and treatment effects and can be applied particularly during open-label extensions and single-arm trials without placebo comparisons.","journal":"medRxiv","year":2025,"id":562330,"datarank":0.0,"base_score":0.0,"endowment":0.0,"self_citation_contribution":0.0,"citation_network_contribution":0.0,"self_endowment_contribution":0.0,"citer_contribution":0.0,"corpus_percentile":null,"corpus_rank":null,"citation_count":0,"citer_count":0,"citers_with_citation_signal":0,"citers_with_endowment":0,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":0.8523,"is_data_producer":false,"deposit_databanks":null,"is_oa":true,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":"2025-01-01","fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":624005,"name":"Yan Li","orcid":"0000-0002-9402-1093","position":1,"is_corresponding":false},{"id":301877,"name":"Eric McDade","orcid":"0000-0002-6764-3866","position":2,"is_corresponding":false},{"id":321049,"name":"Chengjie Xiong","orcid":"0000-0003-0044-4499","position":3,"is_corresponding":false},{"id":230709,"name":"Sarah M. Hartz","orcid":"0000-0002-5429-3799","position":4,"is_corresponding":false},{"id":228359,"name":"Randall J. Bateman","orcid":"0000-0002-7729-1702","position":5,"is_corresponding":false},{"id":675635,"name":"John C. Morris","orcid":"0000-0002-2692-4565","position":6,"is_corresponding":false},{"id":232094,"name":"Lon S. Schneider","orcid":"0000-0002-4636-6150","position":7,"is_corresponding":false},{"id":1214424,"name":"Guoqiao Wang","orcid":"0000-0002-6808-8737","position":0,"is_corresponding":true}],"reference_count":14,"raw_metadata":{"citation_network_status":"fetched"},"created_at":"2026-07-19T02:56:05.550545Z","pmid":"40034778","pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}